<DOC>
<DOCNO>EP-0650953</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Cyclised analogs of metabolites of fatty acids, process for their preparation and pharmaceutical compositions containing them
</INVENTION-TITLE>
<CLASSIFICATIONS>C07C23300	C07D25700	A61K3118	C07C23534	C07D40106	C07C3328	C07C2910	C07D23300	A61K314402	A61K3118	C07C69612	C07D21330	C07C5956	A61K31165	A61K3144	C07C21530	A61K3166	A61P700	C07D21379	A61K31675	A61K3144	C07C1700	C07C23500	A61K31045	A61K314427	C07C4900	A61K31165	C07D23100	C07C49245	C07D21355	C07D23300	C07F938	C07F700	C07C69618	C07F718	C07C3300	A61K31075	A61K31075	C07C4300	C07C3346	C07C31117	C07C43178	C07C3326	C07F940	A61K3166	C07C31116	A61K31135	C07C4720	C07C2962	C07C69732	C07C6900	C07C21500	A61P702	C07C51347	A61K314427	C07C25100	A61K314402	C07C4727	C07D23100	A61K3121	C07C25900	A61K31215	C07C5900	C07C25140	C07C51367	C07D21300	A61P306	C07C25116	C07C43315	C07C31100	A61K314418	C07C23325	C07F900	A61K31135	C07D25700	A61P3500	A61K31045	A61K314418	C07C5948	A61K31675	C07C21528	C07C1726	A61P300	C07D40100	C07C2900	C07C25906	A61P3500	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07C	C07D	A61K	C07C	C07D	C07C	C07C	C07D	A61K	A61K	C07C	C07D	C07C	A61K	A61K	C07C	A61K	A61P	C07D	A61K	A61K	C07C	C07C	A61K	A61K	C07C	A61K	C07D	C07C	C07D	C07D	C07F	C07F	C07C	C07F	C07C	A61K	A61K	C07C	C07C	C07C	C07C	C07C	C07F	A61K	C07C	A61K	C07C	C07C	C07C	C07C	C07C	A61P	C07C	A61K	C07C	A61K	C07C	C07D	A61K	C07C	A61K	C07C	C07C	C07C	C07D	A61P	C07C	C07C	C07C	A61K	C07C	C07F	A61K	C07D	A61P	A61K	A61K	C07C	A61K	C07C	C07C	A61P	C07D	C07C	C07C	A61P	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07C233	C07D257	A61K31	C07C235	C07D401	C07C33	C07C29	C07D233	A61K31	A61K31	C07C69	C07D213	C07C59	A61K31	A61K31	C07C215	A61K31	A61P7	C07D213	A61K31	A61K31	C07C17	C07C235	A61K31	A61K31	C07C49	A61K31	C07D231	C07C49	C07D213	C07D233	C07F9	C07F7	C07C69	C07F7	C07C33	A61K31	A61K31	C07C43	C07C33	C07C311	C07C43	C07C33	C07F9	A61K31	C07C311	A61K31	C07C47	C07C29	C07C69	C07C69	C07C215	A61P7	C07C51	A61K31	C07C251	A61K31	C07C47	C07D231	A61K31	C07C259	A61K31	C07C59	C07C251	C07C51	C07D213	A61P3	C07C251	C07C43	C07C311	A61K31	C07C233	C07F9	A61K31	C07D257	A61P35	A61K31	A61K31	C07C59	A61K31	C07C215	C07C17	A61P3	C07D401	C07C29	C07C259	A61P35	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Compounds of formula (I): 
<
IMAGE
>
 in which A, X, Y, Z, R, R1, R2, R3 and R4 are as defined in the description. These compounds and their physiologically tolerable salts can be used in therapeutics as platelet antiaggregants (antisludges).
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
ADIR
</APPLICANT-NAME>
<APPLICANT-NAME>
ADIR ET COMPAGNIE
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
GREE DANIELLE
</INVENTOR-NAME>
<INVENTOR-NAME>
GREE RENE
</INVENTOR-NAME>
<INVENTOR-NAME>
HACHEM ALI MOHAMMED
</INVENTOR-NAME>
<INVENTOR-NAME>
LE FLOC H YVES
</INVENTOR-NAME>
<INVENTOR-NAME>
ROLLAND YVES
</INVENTOR-NAME>
<INVENTOR-NAME>
SIMONET SERGE
</INVENTOR-NAME>
<INVENTOR-NAME>
VERBEUREN TONY
</INVENTOR-NAME>
<INVENTOR-NAME>
GREE, DANIELLE
</INVENTOR-NAME>
<INVENTOR-NAME>
GREE, RENE
</INVENTOR-NAME>
<INVENTOR-NAME>
HACHEM, ALI MOHAMMED
</INVENTOR-NAME>
<INVENTOR-NAME>
LE FLOC'H, YVES
</INVENTOR-NAME>
<INVENTOR-NAME>
ROLLAND, YVES
</INVENTOR-NAME>
<INVENTOR-NAME>
SIMONET, SERGE
</INVENTOR-NAME>
<INVENTOR-NAME>
VERBEUREN, TONY
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Compounds of formula (I) 

 
   wherein: 


A
 represents a divalent hydrocarbon radical containing from 2 to 10 carbon atoms in linear or 
branched chain and optionally containing one or more unsaturations in the form of double and 

triple bonds, 
R
 is selected from a halogen atom, selected from fluorine, chlorine, bromine and iodine, a 
radical -OR', -COOR', -COR', P(O)(OR')
2
, -CH=N-OR', -CONHR', -CH=NR", -CH=NAr, 
-NHSO
2
Ar, -CON(OH)R', -NHR', -NHCOR', -CH=N-NHAr, 

 
and an 

optionally substituted imidazolyl, pyrazolyl or tetrazolyl radical, 
R'
 is selected from a hydrogen atom and a linear or branched alkyl radical containing from 1 
to 6 carbon atoms, 
R"
 represents a linear or branched alkyl radical containing from 1 to 6 carbon atoms, 
Ar
 represents an optionally substituted aryl radical selected from the radicals phenyl and 
naphthyl, 
R
1
 and 
R
2
 each represents a hydrogen atom or together form a bond, 
R
3
 is selected from a hydrogen atom and an alkyl radical containing from 2 to 10 carbon 
atoms in linear or branched chain,  
R
4
 represents a hydrocarbon radical containing from 2 to 10 carbon atoms in linear or 
branched chain and optionally containing one or more unsaturations in the form of double and 

triple bonds, 
X
 represents a CH group or a nitrogen atom, 
Y
 and 
Z
 each represents, independently of the other, a valency bond or a para-phenylene 
group, 
it being understood that the expression "optionally substituted" denotes that the radical in 
question may optionally be substituted by one or more groups selected from chlorine, 

fluorine, bromine, iodine, amino, alkylamino, dialkylamino, nitro, cyano, alkyl, alkoxy, acyl, 
acyloxy, carboxy, alkoxycarbonyl, amido and carboxamido, 
their stereoisomers, their possible N-oxides and also the pharmaceutically acceptable addition 
salts thereof with an acid or base. 
Compounds according to claim 1, wherein X represents a CH group, their possible 
stereoisomers, N-oxides and pharmaceutically acceptable addition salts with an acid or base. 
Compounds according to claim 1, wherein X represents nitrogen, their possible 
stereoisomers, N-oxides and pharmaceutically acceptable addition salts with an acid or base. 
Compounds according to claim 1, wherein Z represents a valency bond, their possible 
stereoisomers, N-oxides and pharmaceutically acceptable addition salts with an acid or base. 
Compounds according to claim 1, wherein Y represents a valency bond, their possible 

stereoisomers, N-oxides and pharmaceutically acceptable addition salts with an acid or base. 
Compounds according to claim 1, wherein R
3
 represents hydrogen, their possible 
stereoisomers, N-oxides and pharmaceutically acceptable addition salts with an acid or base. 
Compound according to any one of claims 1, 2, 4, 5 and 6, which is sodium (5Z)-6-[(3Z)-(1-hydroxynon-3-en-1-yl)phenyl]hex-5-enoate, 

and its stereoisomers.  
 
Process for the preparation of compounds of formula (I) according to claim 1, 
characterised in that the aldehyde functions of the compound of formula (II) : 


 
   wherein X is as defined for formula (I)
 
are protected with methyl orthoformate, at room temperature, in an anhydrous alcoholic 

solvent, in the presence of an ammonium salt, to obtain the bis-acetal of formula (III) : 

 
   wherein X is as defined above,
 
which is converted into an acetal aldehyde of formula (IV) : 


 
   wherein X is as defined above,
 
by the action of an aqueous solution of sulphuric acid in an organic solvent in the presence of 

silica,
 
which compound of formula (IV) is reacted : 


A) - when the group Y defined in formula (I) represents a bond and the radical R
4
 of the 
same desired compound of formula (I) contains one or more unsaturations (designated 

the radical R
4A
),
  
 

with trimethylsulphonium methyl sulphate, in the presence of an aqueous sodium 
hydroxide solution, in a solvent, at room temperature, to obtain the epoxide of formula 

(V
A
): 

 
   wherein X is as defined above,
 
which, contacted in an anhydrous polar solvent, at 0°C, with a compound of formula 

(VI) : 

H-R
5A
 
   wherein R
5A
 is such that -R
4A
 = -CH
2
-R
5A
 where R
4A
 is as defined above,
 
that has previously been reacted with a solution of butyllithium in hexane in the 

presence of a cation chelator, yields the compound of formula (VI
A
) : 

 
   wherein X and R
4A
 are as defined above, 
B) when the group Y of the compound of formula (I) represents a bond and the radical R4 
of the same desired compound of formula (I) represents a saturated hydrocarbon group 

(designated the radical R
4B
),
 
with the Grignard reagent of formula (V
B
) : 

R
5B
-Mg-Hal    (V
B
)
  
 

   wherein R
5B
 is such that R
4B
 = -CH
2
-R
5B
 where R
4B
 is as defined above and 
Hal is a halogen atom,
 
in anhydrous THF, at a temperature of -50°C, to yield the compound of formula (VI
B
) : 

 
   wherein X is as defined for formula (I) and R
4B
 is as defined for formula (V
B
) 
C) - when the group Y of the compound of formula (I) represents a para-phenylene group, 
with the compound of formula of formula (V
C
) : 

 
   wherein R
4
 is as defined above,
 
in anhydrous THF, at a temperature of -50°C, to yield the compound of formula (VI
C
) : 

 
   wherein X and R
4
 are as defined above, 
 
the totality of the compounds of formulae (VI
A
), (VI
B
) and (VI
C
) forming the totality of the 
compounds of formula (VI) :  

 

 
   wherein X, Y and R
4
 are as defined above,
 
which may, if desired, be subjected to oxidation with a mixture of oxalyl chloride and 

dimethyl sulphoxide, in a chlorinated solvent, to obtain the compound of formula (VII) : 

 
   wherein X and R
4
 are as defined above,
 
which is 


either
 A) treated with a reagent of formula (VIII
A
) : 

Li-R'
3
    (VIII
A
)
 
   wherein R'
3
 represents an alkyl radical containing from 2 to 10 carbon atoms 
in linear or branched chain,
 
under the same conditions as the compound of formula (V
B
), to yield the compound of 
formula (IX
A
) : 

 
 

   wherein R'
3
, R
4
, X and Y are as defined above, 
or :
 B) treated with a reagent of formula (VIII
B
) : 

 
   wherein R
3
 is as defined above,
 
under the same conditions is those used for obtaining the compound of formula (VI
C
), to 
yield the compound of formula (IX
B
) : 

 
   wherein R
3
, R
4
, X and Y are as defined above, 
 
the totality of the compounds of formula (VI), (IX
A
) and (IX
B
) forming the totality of the 
compounds of formula (IX) : 


 
   wherein R
3
, R
4
, X, Y and Z are as defined above,
  
 

the alcohol function of which compounds of formula (IX) is protected by tert-butyl-diphenylsilyl 
chloride, in the presence of imidazole in a solvent, at room temperature, to yield the 

compound of formula (X) : 

 
   wherein X, Y Z, R
3
 and R
4
 are as defined above,
 
the acetal function of the compound of formula (X) then being converted in a manner identical 

to that used for the compound of formula (III) into the aldehyde of formula (XI) : 

 
   wherein X, Y, Z, R
3
 and R
4
 are as defined above,
 
which is then subjected to a Wittig reaction with a compound of formula (XII) : 


 
   wherein A is as defined above,
 
previously dissol
ved in an anhydrous solvent, in the presence of lithium bis(trimethylsilyl)amide 
and hexamethylphosphotriamide (HMPA), at a temperature of -80°C, to obtain the 

compound of formula (XIIIa) :  
 


 
   wherein A, X, Y, Z, R
3
 and R
4
 are as defined above,
 
which may, if desired, be converted according to a conventional esterification technique into a 

compound of formula (XIIIb) : 

 
   wherein A, X, Y, Z, R", R
3
 and R
4
 are as defined above,
 
the corresponding Z and E isomers of which compounds of formulae (XIIIa) and (XIIIb) are 

separated on a silica column, then optionally subjected to a reaction for the deprotection of the 
alcohol function by the action of tetraalkylammonium fluoride in a polar solvent, at 0°C, to 

obtain the alcohols of formulae (XIVa) and (XIVb) respectively : 

 
   wherein A, X, Y, Z, R", R
3
 and R
4
 are as defined above,
  
 

the compound of formula (XIVa) then optionally being converted, after temporary protection 
of the alcohol function, into the amide of formula (XIVc): 


 
   wherein A, X, Y, Z, R', R
3
 and R
4
 are as defined above,
 
it also being possible for the ester of formula (XIIIb) to be hydrolysed directly, in accordance 

with the method described for obtaining the acid of formula (XIVa), then optionally converted 
into its acyl chloride of formula (XIV) : 


 
   wherein A, X, Y, Z, R
3
 and R
4
 are as defined above,
 
by the action of oxalyl chloride in the presence of N,N-dimethylformamide in THF at 0°C, 

which acyl chloride of formula (XIV) is immediately treated with an N-alkylhydroxylamine 
hydrochloride of formula (XV) : 


 
   wherein R' is as defined above,
  
 

in basic medium, at 0°C, to yield, after freeing the alcohol function, the hydroxamic acid of 
formula (XIVd) : 


 
   wherein A, X, Y, Z, R', R
3
 and R
4
 are as defined above,
 
it also being possible for the acyl chloride of formula (XIV) to be treated immediately with a 

hydrazine of formula H
2
N-NHAr wherein Ar is as defined above to yield, after freeing the 
alcohol function, the corresponding hydrazide of formula (XIVe) : 


 
   wherein A, X, Y, Z, Ar, R
3
 and R
4
 are as defined above,
 
the ester of formula (XIIIb) likewise leading, in accordance with conventional reduction 

techniques and after freeing the alcohol function protected in silylated ether form, to the 
alcohol and ether of formula (XIVf): 


  
 

   wherein A, X, Y, Z, R', R
3
 and R
4
 are as defined above,
 
themselves resulting, after temporary protection of the α-aromatic alcohol function, in the 

halogenated compounds of formula (XIVg) : 

 
   wherein A, X, Y, Z, R
3
 and R
4
 are as defined above and Hal represents a 
halogen atom selected from fluorine, chlorine, bromine and iodine,
 
enabling the preparation of the phosphonates of formula (XIVh) : 


 
   wherein A, X, Y, Z, R', R
3
 and R
4
 are as defined above,
 
or, by reaction with a compound of formula (XVI) : 


H-B
1
 
   wherein B
1
 represents a -NHR", 

 
optionally substituted 

imidazolyl, optionally substituted pyrazolyl or optionally substituted tetrazolyl group, 
R" being as defined above,
  
 

under conventional and appropriate operating conditions, enabling the preparation of the 
compounds of formula (XVIa) : 


 
   wherein A, B
1
, X, Y, Z, R
3
 and R
4
 are as defined above,
 
the amines of formula (XVIb) : 


 
   wherein A, X, Y, Z, R
3
 and R
4
 are as defined above,
 
then being obtained by preparation of the azide, starting from the precursor halogenated 

compound of formula (XIVg), followed by hydrogenation of that azide,
 
which amines of formula (XVIb) may be converted by the action of a compound of formula 

(XVI'): 

Hal-B
2
 
   wherein B
2
 represents -SO
2
Ar or -COR' and Hal, Ar and R' are as defined 
above,
 
into compounds of formula (XVIc) :  

 

 
   wherein A, B
2
, X, Y, Z, R
3
 and R
4
 are as defined above,
 
the totality of the compounds of formulae (XVIa), (XVIb) and (XVIc) together forming the 

totality of the compounds of formula (XIVi) : 

 
   wherein A, X, Y, Z, R
3
 and R
4
 are as defined above and B represents B
1
, B
2
 or 
a NH
2
 group,
 
it also being possible for the ester of formula (XIIIb) : 


1/ - to be hydrolysed to the corresponding acid and then treated with a compound of formula 
Li-R" wherein R" is as defined above to yield, after freeing the alcohol function which has 

until then been protected in silylated ether form, the ketones of formula (XIVj) : 

  
 

   wherein A, X, Y, Z, R", R
3
 and R
4
 are as defined above, 
2/ - to be treated with an equivalent of diisobutylaluminium hydride (DIBAL) at low temperature 
to yield, after freeing the alcohol function, the aldehydes of formula (XIVk) : 


 
   wherein A, X, Y, Z, R
3
 and R
4
 are as defined above, 
 
it being possible for those aldehydes of formula (XIVk) to be 


either :
 α) treated with hydroxylamine to yield the oximes of formula (XIVl) : 

 
   wherein A, X, Y, Z, R
3
 and R
4
 are as defined above,
 
it being possible for the oximes of formula (XIVl) in turn to be alkylated 
to 
compounds of formula (XIVm) : 


 
 

   wherein A, X, Y, Z, R", R
3
 and R
4
 are as defined above,
 
by a reagent of formula W-R" wherein W represents a leaving group and R" is as 

defined above, 
or :
 β) treated with an amine of formula H
2
N-R" wherein R" is as defined above to yield 
the imines of formula (XIVn) : 


 
   wherein A, X, Y, Z, R", R
3
 and R
4
 are as defined above, 
 
the totality of the compounds of formulae (XIVa) to (XIVn) forming the totality of the 

compounds of formula (XVII) : 

 
   wherein A, X, Y, Z, R, R
3
 and R
4
 are as defined above,
 
which, optionally subjected to hydrogenation according to a conventional technique, yield the 

compounds of formulae (XVIII) : 

  
 

   wherein A, X, Y, Z, R, R
3
 and R
4
 are as defined above,
 
the totality of the compounds of formulae (XVII) and (XVIII) forming the totality of the 

compounds of formula (I) which, if necessary, are purified according to a conventional 
purification technique and, if desired, are separated into their isomers by a conventional 

separation technique, and, optionally, are converted into their N-oxides and/or their 
pharmaceutically acceptable addition salts with an acid or base. 
Process for the preparation of compounds of formula I according to claim 3 wherein X 
represents a nitrogen atom, characterised in that the starting material is 2,6-dimethanolpyridine, 

one of the alcohol functions of which is protected by tert-butyl-diphenyl-silyl 
chloride to obtain the compound of formula (XIX) : 


 
which is then oxidised to the aldehyde of formula (XX) : 


 
which is then subjected to the Wittig reaction described for obtaining the compound of 

formula (XIIIb), to yield the compound of formula (XXI) :  
 


 
   wherein A and R" are as defined above,
 
the alcohol function of which is deprotected according to the method used for obtaining the 

compound of formula (XIVa), then oxidised to the aldehyde according to the method 
described for the compound (XVIII), thus yielding the compound of formula (XXII) : 


 
   wherein A and R" are as defined above,
 
which is then treated in an analogous manner to the compound of formula (IV), in accordance 

with the meanings of Y and R
4
, to yield the compounds of formula (XXIII) : 

 
   wherein A, Y, R" and R
4
 are as defined above,
  
 

which are then optionally treated in an analogous manner to the compounds of formula (VI) to 
obtain the compounds of formula (XXIV) : 


 
   wherein A, Y, Z, R", R
3
 and R
4
 are as defined above,
 
the ester function of which is optionally modified in an identical manner to the methods used 

for obtaining the compounds (XIVa) to (XIVn) to yield the compounds of formula (XXV): 

 
   wherein A, Y, Z, R, R
3
 and R
4
 are as defined above,
 
which are optionally subjected to hydrogenation according to the technique described for the 

hydrogenation of the compounds of formula (XVII) in order to obtain the compounds of 
formula (XXVI) : 


  
 

   wherein A, Y, Z, R, R
3
 and R
4
 are as defined above,
 
the totality of the compounds of formulae (XXV) and (XXVI) forming the totality of the 

compounds of formula (XXVII) : 

 
   wherein A, R, R
1
, R
2
, R
3
, R
4
, Y and Z are as defined above,
 
a particular case of the compound of formula (I) wherein X represents nitrogen, which, if 

necessary, are purified according to a conventional purification technique and which, if 
desired, are separated into their isomers by a conventional separation technique and which, if 

necessary, are converted into their pharmaceutically acceptable addition salts with an acid or 
base. 
Pharmaceutical compositions comprising as active ingredient at least one compound 
according to any one of claims 1 to 7, alone or in combination with one or more 

pharmaceutically acceptable, inert, non-toxic carriers. 
Pharmaceutical composition according to claim 10 having an anti platelet-aggregation 
activity and useful in the treatment of disorders resulting from or associated with platelet 

adhesion pathologies and especially in the case of thromboembolism, by dissolving blood 
clots, in the case of pulmonary embolism, arterial embolism of the extremities, myocardial 

infarct, atherosclerosis, malignant cancer, and also in maintaining blood homeostasis, in 
particular in extracorporeal circulation. 
</CLAIMS>
</TEXT>
</DOC>
